Harpoon Therapeutics, Inc
4000 Shoreline Court, Suite 250
South San Francisco
About Harpoon Therapeutics, Inc
Harpoon Therapeutics is an immuno-oncology company using a proprietary technology platform focused on T cell engagement to discover and develop novel biologics for the treatment of cancer and other diseases. The company is developing a broad portfolio of drug candidates, and plans to develop its own oncology products in the U.S., as well as selectively partner other products to access global markets.
CEO: Gerald McMahon, Ph.D.
30 articles with Harpoon Therapeutics, Inc
Harpoon Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update
Lead Tri-specific T cell Activating Construct (TriTAC) candidate, HPN424, continues to advance in a Phase 1 clinical trial for the treatment of prostate cancer
A summary of IPOs from companies in the biotech and pharma world since February 1, 2019.
Harpoon Therapeutics, Inc. announced the pricing of its initial public offering of 5,400,000 shares of its common stock at a price to the public of $14.00 per share.
The government shutdown threw a wrench into several biotech company’s plans for initial public offerings (IPOs). Although the government is only guaranteed to stay open until February 15, several biotechs are working to get their IPOs launched in that window. Here’s a look.
Harpoon Therapeutics Announces Preliminary Safety and Pharmacology Data from its HPN424 Phase 1 Trial in Prostate Cancer
Initial data shows HPN424 serum exposure supports weekly dosing Changes in blood-derived tumor cell and serum biomarkers consistent with T cell activation HPN424 dose escalation proceeding to identify Phase 2 therapeutic dose
A summary of IPOs from companies in the biotech and pharma world since December 1, 2018.
Harpoon initiated a Phase I trial for its lead candidate for prostate cancer earlier this summer.
Harpoon Therapeutics Announces Filing of Registration Statement for Proposed Initial Public Offering
Harpoon Therapeutics, Inc announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (the “SEC”) relating to a proposed initial public offering of its common stock
Harpoon Therapeutics Presents Preclinical Data Supporting Development of HPN217, a New BCMA-Targeting TriTAC, at the 2018 American Society of Hematology (ASH) Annual Meeting
Harpoon’s Third Product Candidate is Slated for Clinical Development in 2019
Proceeds to Advance Pipeline of Cancer Immunotherapies
Harpoon Therapeutics Unveils ProTriTAC Platform: A Novel, Protease-Activated T Cell Engager Platform Designed to Access a Broad Landscape of Solid Tumor Targets
Harpoon Therapeutics, Inc ("Harpoon"), a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases, today presented preclinical data supporting the development of a new Protease-activated Tri-specific T cell Activating Construct ("ProTriTAC") platform.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
Harpoon Therapeutics Announces Appointment of Ms. Georgia L. Erbez to Chief Financial Officer and Promotion of Holger Wesche, PhD, to Chief Scientific Officer
Ms. Erbez previously served as Chief Business Officer and Chief Financial Officer of Zosano Pharma, a therapeutics company focused on migraine, from 2016 through 2018.
Taiho Ventures, the corporate venture capital arm of Taiho Pharmaceutical, has pumped up its venture capital pool from $50 million to $300 million. It also indicates it plans to accelerate its “open innovation” through the investments.
10/15/2018Who mixed things up in the biotech world this past week? Pfizer announces its leadership team, Rheos gets a new COO, and board of directors updates from multiple biopharma companies.
She is a seasoned executive who brings strong financial, operations and business development experience, which will be instrumental as Harpoon continues to advance its immunotherapy product candidates
Harpoon Therapeutics, Inc. announced today that it has appointed Natalie R. Sacks, M.D., as Chief Medical Officer.
Jonathan Drachman, M.D., former CMO of Seattle Genetics, Brings Immuno-Oncology Expertise to Board.
Life Sciences Veteran Scott Myers Appointed to the Board of Directors
Harpoon Therapeutics Treats First Patient with HPN424 in Phase 1 Clinical Trial of Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients
Harpoon Therapeutics, today that the first patient has been treated with HPN424 in a Phase 1 clinical study of metastatic castration-resistant prostate cancer patients.